📰 AbbVie, a biopharmaceutical company, is investing $223 million to expand its manufacturing facility in Singapore. The investment will increase the plant’s capacity to produce and supply drugs to global markets. This expansion is a response to the growing demand for AbbVie’s products and will contribute to the company’s long-term growth strategy. The Singapore plant plays a critical role in AbbVie’s global supply chain. 🌿🔬💉
📢 AbbVie Supercharges Singapore Plant with $223m Investment
Introduction:
AbbVie, a global biopharmaceutical company, has announced plans to invest $223 million in expanding its manufacturing plant in Singapore. The investment aims to increase the plant’s manufacturing capacity to meet the growing demand for its biologic medicines.
Main points:
- AbbVie plans to invest $223 million in expanding its manufacturing plant in Singapore.
- The investment aims to increase the plant’s manufacturing capacity to meet the growing demand for its biologic medicines.
- The expansion project is expected to be completed by 2021 and will include the construction of a new building and the installation of additional manufacturing equipment.
- The expanded facility will support the production of AbbVie’s key products, including Humira, which is used to treat various autoimmune diseases.
- This investment demonstrates AbbVie’s commitment to meeting the needs of patients and ensuring a stable supply of its biologic medicines.
Conclusion:
AbbVie’s $223 million investment in expanding its manufacturing plant in Singapore is a significant move to meet the growing demand for its biologic medicines. The expansion project, expected to be completed by 2021, will increase the plant’s manufacturing capacity and support the production of key products like Humira. This investment highlights AbbVie’s commitment to patient care and ensuring a stable supply of its biologic medicines.
